Long‐Term Safety of Rituximab in Rheumatoid Arthritis: Analysis From the SUNSTONE Registry
2018
Objective
To evaluate the long‐term safety of rituximab in an observational cohort of patients with rheumatoid arthritis (RA) who had an inadequate response to ≥1 anti–tumor necrosis factor therapy in the US (SUNSTONE [Study of the Safety of Rituxan in Patients With Rheumatoid Arthritis After an Inadequate Response to Previous Anti‐TNF Therapy] registry).
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
35
References
15
Citations
NaN
KQI